Krishan Jethwa: Interpreting the benefit of RAPIDO Trial in high-risk rectal cancer

Krishan Jethwa, Assistant Professor of Radiation Oncology at Mayo Clinic, shared on X:

“A consideration in interpreting the benefit for high-risk rectal cancer in RAPIDO Trial was that only ~ 40% got post-op chemo in the CRT arm leading some to hypothesize that post-op chemo would have decreased DM, LRR, and DrTF, thus skewing the primary result towards the null.”

Source: Krishan Jethwa/X